Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

FDA approves Posimir for post-surgical pain following arthroscopic subacromial decompression

Feb. 3, 2021

New mouse model points to mitochondrial dynamics as key to neurodegeneration

Feb. 3, 2021

Algernon repurposes a psychedelic drug as potential treatment for stroke

Feb. 3, 2021

Pharmaleads patents neprilysin and aminopeptidase N inhibitors

Feb. 2, 2021

New LRRK2 inhibitors discovered at E-Scape Bio

Feb. 2, 2021

Noveome and WRAIR collaborate to develop ST-266 for traumatic brain injury

Feb. 2, 2021

Phase II study of CTP-692 in schizophrenia does not meet primary or secondary endpoints

Feb. 2, 2021

Promising phase I data presented for tau monoclonal antibody PNT-001

Feb. 2, 2021

Life Science Institute initiates exploratory clinical trial of CL-2020 as treatment of ALS

Feb. 1, 2021

Growth factors linked to lysosomes, Parkinson's risk

Feb. 1, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 20, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...